Mark Tyson, Associate Professor of Urology at Mayo Clinic in Arizona, posted on X:
“Analysis of intravesical gem at MSK: 12mo HGRFS was 52% in BCG-u bladder cancer.
Off-trial patients did better (66%) vs. on-trial (25%)—highlighting selection in trials vs realworld. Gem/doce’s “standard” status needs prospective validation IMO. Need RCT. Love this.”
More posts featuring bladder cancer.